Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Juan Pablo FriasMichael A NauckJoanna VanCharles BensonRoss BrayXuewei CuiZvonko MilicevicShweta UrvaAxel HauptDeborah A RobinsPublished in: Diabetes, obesity & metabolism (2020)
Tirzepatide treatment for 12 weeks resulted in clinically significant reductions in HbA1c. This suggests that lower starting doses and smaller dose increments are associated with a more favourable side effect profile.